Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADCT 
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: ADCT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 431.32% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.24M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 6 | Beta 1.89 | 52 Weeks Range 1.05 - 4.80 | Updated Date 12/2/2025 |
52 Weeks Range 1.05 - 4.80 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.3567 | Actual -0.3 |
Profitability
Profit Margin -221.97% | Operating Margin (TTM) -186.23% |
Management Effectiveness
Return on Assets (TTM) -23.98% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 415199577 | Price to Sales(TTM) 6.98 |
Enterprise Value 415199577 | Price to Sales(TTM) 6.98 | ||
Enterprise Value to Revenue 5.52 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 123877111 | Shares Floating 107868472 |
Shares Outstanding 123877111 | Shares Floating 107868472 | ||
Percent Insiders 14.04 | Percent Institutions 58.6 |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA, founded in 2011, is a late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors.
Core Business Areas
- Oncology Drug Development: Focuses on developing antibody drug conjugates (ADCs) for various types of cancers.
- Clinical Trials and Research: Conducts clinical trials to evaluate the safety and efficacy of its ADC candidates.
- Commercialization: Commercializes approved ADC therapies.
Leadership and Structure
The company is led by a team of experienced biotechnology executives and has a hierarchical organizational structure with departments focused on research, development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- Zynlonta (loncastuximab tesirine-lpyl): Zynlonta is an ADC approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It has a significant market opportunity within the DLBCL treatment landscape, competing with other targeted therapies and chemotherapies. Worldwide revenue for Zynlonta were $79.8 million in 2022. Competitors include Roche (Polivy) and other chemotherapy regimens.
- Pipeline ADC Candidates: ADC Therapeutics has multiple ADC candidates in various stages of clinical development targeting different cancer types. These candidates represent future growth opportunities. Competitors vary based on the specific target and cancer type.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and growing market driven by an aging population, increasing cancer incidence, and advances in cancer treatment. The ADC segment is a rapidly evolving area with significant potential.
Positioning
ADC Therapeutics is positioned as a leader in the ADC space with a focus on hematological malignancies and solid tumors. Its competitive advantage lies in its proprietary ADC technology platform.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be hundreds of billions of dollars. ADC Therapeutics is targeting specific segments within this market, and its position within the TAM will depend on the success of its pipeline candidates and market penetration of Zynlonta.
Upturn SWOT Analysis
Strengths
- Proprietary ADC technology platform
- Approved product (Zynlonta)
- Experienced management team
- Strong pipeline of ADC candidates
Weaknesses
- Reliance on single approved product
- Competition in the oncology market
- High R&D costs
- Cash burn
Opportunities
- Expansion of Zynlonta label
- Advancement of pipeline candidates
- Strategic partnerships
- Acquisition targets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- RHHBY
- LLY
- MRK
Competitive Landscape
ADC Therapeutics competes with both established pharmaceutical companies and other biotechnology companies in the oncology market. Its advantage lies in its specialized ADC technology, but it faces challenges from companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and regulatory approvals, mainly the approval of Zynlonta.
Future Projections: Future growth is dependent on the expansion of Zynlonta's label and the success of its pipeline candidates. Analyst estimates vary, but generally project revenue growth over the next few years, though profitability may be challenging.
Recent Initiatives: Recent initiatives include ongoing clinical trials, seeking regulatory approvals for new indications, and exploring strategic partnerships.
Summary
ADC Therapeutics is a biotechnology company with an approved ADC product and a promising pipeline. Its success depends on the commercial success of Zynlonta and the progress of its pipeline. The company faces significant competition and requires substantial investment in R&D. While the ADC platform is compelling, the financial performance and current market conditions pose risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimations and may not be precise. Future projections are subject to change based on market conditions and company performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.